期刊名称：Proceedings of the National Academy of Sciences
印刷版ISSN：0027-8424
电子版ISSN：1091-6490
出版年度：2021
卷号：118
期号：38
DOI：10.1073/pnas.2020385118
语种：English
出版社：The National Academy of Sciences of the United States of America
摘要：Significance
Patients with rheumatoid arthritis (RA) are susceptible to heart failure accompanied by diastolic dysfunction. It is unknown what causes diastolic dysfunction in RA, and current therapies do not reduce the risk of heart problems. Here, we characterize a murine model of arthritis, which mirrors the diastolic dysfunction observed in RA patients; this dysfunction is associated with fibrous tissue formation, enlargement of the heart, and changes in the number/type of inflammatory cells within the heart. Importantly, treatment with the protein Annexin A1 not only halts the progression of diastolic dysfunction, but, when given at a later stage, it reverses established diastolic dysfunction and attenuates cardiac remodeling in arthritic mice. This model can help develop treatments for heart failure in RA.
Rheumatoid arthritis (RA) carries a twofold increased incidence of heart failure with preserved ejection fraction, accompanied by diastolic dysfunction, which can lead to death. The causes of diastolic dysfunction are unknown, and there are currently no well-characterized animal models for studying these mechanisms. Current medications for RA do not have marked beneficial cardio-protective effects. K/BxN F1 progeny and KRN control mice were analyzed over time for arthritis development, monitoring left ventricular diastolic and systolic function using echocardiography. Excised hearts were analyzed by flow cytometry, qPCR, and histology. In pharmacological experiments, K/BxN F1 mice were treated with human recombinant AnxA1 (hrAnxA1, 1 μg/mouse) or vehicle daily. K/BxN F1 mice exhibited fully developed arthritis with normal cardiac function at 4 wk; however, by week 8, all mice displayed left ventricular diastolic dysfunction with preserved ejection fraction. This dysfunction was associated with cardiac hypertrophy, myocardial inflammation and fibrosis, and inflammatory markers. Daily treatment of K/BxN F1 mice with hrAnxA1 from weeks 4 to 8 halted progression of the diastolic dysfunction. The treatment reduced cardiac transcripts of proinflammatory cytokines and profibrotic markers. At the cellular level, hrAnxA1 decreased activated T cells and increased MHC II
low macrophage infiltration in K/BxN F1 hearts. Similar effects were obtained when hrAnxA1 was administered from week 8 to week 15. We describe an animal model of inflammatory arthritis that recapitulates the cardiomyopathy of RA. Treatment with hrAnxA1 after disease onset corrected the diastolic dysfunction through modulation of both fibroblast and inflammatory cell phenotype within the heart.
